drugset / Trial / NCT01603069

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

NCT01603069

Phase 2 Completed 51 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.

Timeline

Start
2012-10
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Verdiperstat Small molecule 300 mg Oral
Comparator Verdiperstat Small molecule 600 mg Oral

Indications